Report: IPOs and government support can boost the Australian life sciences industry

18 February 2014

Despite a relatively flat December quarter for the PricewaterhouseCoopers Life Sciences Index, it was the end of a very successful calendar year for the Life Sciences sector, according to a new PwC report a report on the listed Australian pharmaceutical, biotechnology and medical devices markets and the broader Life Sciences industry.

In Cautious optimism: The Life Sciences boom and lessons from the past, the report states that a resurgent initial public offering (IPO) market and increased media coverage leave the sector primed for a strong 2014. The current success of the Life Sciences sector gives rise to the question; in the 10 years since the last Australian Biotech boom, what has the sector learnt and how can it capture more value to truly capitalize on its success?

A busy quarter for IPO activity

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK